• OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial americanpharmaceuticalreview
    November 10, 2018
    OncoSec announced the first patient has been treated in KEYNOTE-890, a Phase 2 clinical trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electropora
PharmaSources Customer Service